Lancovutide

兰考韦泰

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLancovutide
Drug Alias Name耐久霉素Duramycin杜拉霉素2622U90PA-48009 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionChloride channel agonistsCytosolic phospholipase A2 inhibitors
TargetsChloride channelCytosolic phospholipase A2
Therapy Area/IndicationsXerophthalmiaPulmonary Disease, Chronic ObstructiveCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAop Orphan PharmaceuticalsGlaxosmithkline PlcUniversity Of North Carolina At Chapel Hill +[4] 
Active IndicationsN/A
Inactive IndicationsXerophthalmiaPulmonary Disease, Chronic ObstructiveCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksDrugBank